GLAXO.NS Glaxosmithkline Pharmaceuticals Ltd.
Price history
Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.
Technical indicators
ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.
MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.
Delivery volume
| Date | Traded Qty | Delivery Qty | Delivery % |
|---|---|---|---|
| 2026-08-28 | 135782 | 87780 | 64.65% |
| 2026-08-27 | 229414 | 131640 | 57.38% |
| 2026-08-26 | 111084 | 43196 | 38.89% |
| 2026-08-25 | 174436 | 117625 | 67.43% |
| 2026-08-24 | 80140 | 38341 | 47.84% |
| 2026-08-21 | 86586 | 35426 | 40.91% |
| 2026-08-20 | 304052 | 169939 | 55.89% |
| 2026-08-19 | 1374693 | 438502 | 31.90% |
| 2026-08-18 | 477841 | 267165 | 55.91% |
| 2026-08-17 | 84337 | 59752 | 70.85% |
| 2026-08-14 | 94952 | 71044 | 74.82% |
| 2026-08-13 | 59367 | 35504 | 59.80% |
| 2026-08-12 | 64718 | 40205 | 62.12% |
| 2026-08-11 | 34056 | 16789 | 49.30% |
| 2026-08-10 | 29273 | 17088 | 58.37% |
| 2026-08-07 | 34991 | 20899 | 59.73% |
| 2026-08-06 | 40361 | 22631 | 56.07% |
| 2026-08-05 | 51205 | 28516 | 55.69% |
| 2026-08-04 | 99739 | 50034 | 50.16% |
| 2026-08-03 | 89406 | 47165 | 52.75% |
Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers GLAXO.NS to fetch more history.
Insider trading activity
| Disclosed | Person | Category | Type | Mode | Quantity | Value (₹) | Resulting stake | |
|---|---|---|---|---|---|---|---|---|
| 30 Mar 2017 | Castleton Investment Ltd | Promoter Group | Sell | Inter-se-Transfer | 3192238 | 8698848550 | 0.00% | |
| 30 Mar 2017 | GlaxoSmithKline Pte Ltd | Promoters | Buy | Inter-se-Transfer | 3192238 | 8698848550 | 28.10% |
SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers GLAXO.NS to fetch more.
Extract this company (financials + ratios + citations): CSV · XLSX
Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score
Ratios
This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.
Growth & earnings trend
Revenue & Profit CAGR
Operating Margin Trend
ROCE Trajectory
Earnings Quality
Net profit or operating cash flow was zero or negative in the base or latest year — a growth-rate comparison isn't defined across a sign change.
Sector-Relative Percentile (Healthcare)
Quarterly trend
| Metric (to shareholders basis) | Q4 FY2023-24 | Q1 FY2024-25 | Q2 FY2024-25 | Q3 FY2024-25 | Q4 FY2024-25 | Q1 FY2025-26 | Q2 FY2025-26 | Q3 FY2025-26 | Q4 FY2025-26 | Q1 FY2026-27 | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹929.80 Cr. | ₹814.65 Cr. | ₹1,010.77 Cr. | ₹949.42 Cr. | ₹974.37 Cr. | ₹805.17 Cr. | ₹979.94 Cr. | ₹1,041.26 Cr. | ₹995.30 Cr. | ₹938.44 Cr. | RevenueFromOperations |
| Net Profit | ₹194.48 Cr. | ₹182.33 Cr. | ₹252.50 Cr. | ₹229.88 Cr. | ₹262.87 Cr. | ₹205.01 Cr. | ₹257.49 Cr. | ₹295.62 Cr. | ₹277.86 Cr. | ₹237.18 Cr. | ProfitOrLossAttributableToOwnersOfParent |
Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers GLAXO.NS to fetch more.
Source document — income statement (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| ProfitLossForPeriod | 10359800000.0 |
| PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital | 169410000.0 |
Source document — balance sheet (FY2025-26, raw filing line items)
View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.
| CurrentAssets | 37847100000.0 |
| CurrentLiabilities | 17791100000.0 |
| EquityAttributableToOwnersOfParent | 22674200000.0 |
| BorrowingsCurrent + BorrowingsNoncurrent | — |